Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PPL022
MIFTS: 58

Papilloma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Papilloma

About this section

MalaCards integrated aliases for Papilloma:

Name: Papilloma 12 56 15 74
Papillomatosis 12 56 15 74

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2615
MeSH 45 D010212
NCIt 51 C3713 C7440
SNOMED-CT 69 23730008 82049002
Sources

Summaries for Papilloma

About this section
Disease Ontology : 12 A cell type benign neoplam that is composed of epithelial tissue on papillae of vascularized connective tissue.

MalaCards based summary : Papilloma, also known as papillomatosis, is related to inverted papilloma and bladder transitional cell papilloma. An important gene associated with Papilloma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Developmental Biology and PI3K-Akt signaling pathway. The drugs Cidofovir and Polihexanide have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and cervix, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 77 A papilloma (plural papillomas or papillomata) (papillo- + -oma) is a benign epithelial tumor growing... more...

Sources

Related Diseases for Papilloma

About this section

Diseases related to Papilloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 587)
# Related Disease Score Top Affiliating Genes
1 inverted papilloma 34.3 CDKN2A KRT13 KRT20 TP53
2 bladder transitional cell papilloma 34.1 CDKN1A TP53
3 frontal sinus inverted papilloma 33.9 KRT13 KRT5
4 inverted transitional papilloma 33.7 CDKN2A KRT5
5 anogenital venereal wart 32.8 CDKN2A TP53 UBE3A
6 urinary tract papillary transitional cell benign neoplasm 32.6 KRT20 TP53
7 li-fraumeni syndrome 32.1 CDKN1A CDKN2A PTEN TP53
8 palmoplantar keratoderma, epidermolytic 31.8 FLG KRT10 KRT14
9 squamous cell carcinoma 31.3 CDKN2A IVL PTEN RB1 TP53
10 suppressor of tumorigenicity 3 31.2 CDKN1A CDKN2A RB1 TP53 UBE3A
11 adenocarcinoma 31.0 CDKN2A PTEN RB1 TP53
12 oral cancer 30.9 CDKN2A KRT13 TP53
13 oropharynx cancer 30.8 CDKN2A KRT14 KRT5 TP53
14 cervical cancer 30.7 CDKN1A CDKN2A KRT14 KRT5 PTEN RB1
15 transitional cell carcinoma 30.7 CDKN2A KRT20 KRT8 PTEN TP53
16 retinoblastoma 30.7 CDKN1A CDKN2A RB1 TP53
17 in situ carcinoma 30.7 CDKN2A KRT14 KRT5 TP53
18 verrucous carcinoma 30.7 CDKN2A KRT10 RB1 TP53
19 bladder cancer 30.6 CDKN1A CDKN2A KRT20 RB1 TP53
20 cervical squamous cell carcinoma 30.6 CDKN2A KRT8 TP53
21 cholangiocarcinoma 30.5 CDKN2A KRT20 KRT8 PTEN TP53
22 squamous cell carcinoma, head and neck 30.5 CDKN1A CDKN2A PTEN RB1 TP53
23 lymphoepithelioma-like carcinoma 30.5 KRT20 KRT5 KRT8
24 ductal carcinoma in situ 30.4 KRT14 KRT5 KRT8 TP53
25 bowenoid papulosis 30.3 CDKN2A FLG
26 keratoacanthoma 30.3 CDKN1A FLG KRT10 TP53
27 esophageal cancer 30.2 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
28 bladder squamous cell carcinoma 30.2 CDKN2A TP53
29 vulvar intraepithelial neoplasia 30.2 KRT10 TP53
30 oral cavity cancer 30.2 IL4 PTEN TP53
31 tongue cancer 30.2 CDKN1A CDKN2A KRT13 TP53
32 endocervical adenocarcinoma 30.1 CDKN2A KRT20 TP53
33 nasal cavity squamous cell carcinoma 30.1 CDKN2A KRT5 KRT8
34 adenosquamous carcinoma 30.1 KRT5 KRT8 TP53
35 keratosis 30.1 FLG IVL KRT10
36 cervical adenocarcinoma 30.0 CDKN1A CDKN2A KRT20 TP53
37 basaloid squamous cell carcinoma 30.0 CDKN2A KRT13 KRT14 KRT8 TP53
38 actinic keratosis 30.0 CDKN2A FLG KRT20 TP53
39 gastric adenocarcinoma 29.8 CDKN2A CDKN2B KRT20 KRT8 PTEN TGFA
40 meningioma, familial 29.8 CDKN2A PTEN TP53
41 lichen planus 29.8 FLG IL4 IVL KRT10 KRT13 TP53
42 small cell cancer of the lung 29.8 CDKN2A KRT20 PTEN RB1 TP53
43 basal cell carcinoma 29.7 IVL KRT10 KRT20 KRT8 TP53
44 glioblastoma 29.7 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
45 adenoid cystic carcinoma 29.6 KRT14 KRT20 KRT5 PTEN TP53
46 large cell acanthoma 29.6 KRT10 KRT14 KRT5
47 lung cancer 29.5 CDKN1A CDKN2A CDKN2B KRT20 PTEN RB1
48 cholesteatoma of middle ear 29.4 FLG KRT10 KRT13 TGFA
49 endometrial cancer 29.3 CDKN1A CDKN2A PTEN RB1 TGFA TP53
50 gastric cancer 29.1 CDKN1A CDKN2A CDKN2B KRT20 PTEN TGFA

Graphical network of the top 20 diseases related to Papilloma:



Diseases related to Papilloma
Sources

Symptoms & Phenotypes for Papilloma

About this section

MGI Mouse Phenotypes related to Papilloma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 AMOT CDKN1A CDKN2A IL4 KRT14 KRT5
2 digestive/alimentary MP:0005381 10.22 CDKN1A CDKN2A IL4 KRT14 KRT5 KRT8
3 mortality/aging MP:0010768 10.22 AMOT CDKN1A CDKN2A CDKN2B IL4 KRT14
4 integument MP:0010771 10.2 CDKN1A CDKN2A CDKN2B IL4 KRT14 KRT5
5 endocrine/exocrine gland MP:0005379 10.19 CDKN1A CDKN2A CDKN2B IL4 KRT14 PTEN
6 embryo MP:0005380 10.11 AMOT CDKN1A CDKN2A KRT8 PTEN RB1
7 craniofacial MP:0005382 10.08 CDKN1A IL4 KRT14 KRT5 RB1 TGFA
8 adipose tissue MP:0005375 10.02 CDKN1A KRT14 PTEN RB1 TGFA TP53
9 liver/biliary system MP:0005370 9.98 CDKN1A CDKN2A IL4 KRT8 PTEN RB1
10 no phenotypic analysis MP:0003012 9.92 CDKN1A CDKN2A CDKN2B IL4 KRT5 RB1
11 neoplasm MP:0002006 9.91 CDKN1A CDKN2A CDKN2B KRT14 PTEN RB1
12 reproductive system MP:0005389 9.9 CDKN1A CDKN2A CDKN2B IL4 KRT14 KRT8
13 pigmentation MP:0001186 9.65 CDKN2A KRT14 PTEN RB1 TP53
14 respiratory system MP:0005388 9.5 CDKN1A CDKN2A IL4 KRT14 PTEN RB1
15 vision/eye MP:0005391 9.23 CDKN1A CDKN2A IL4 KRT14 PTEN RB1
Sources

Drugs & Therapeutics for Papilloma

About this section

Drugs for Papilloma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 283)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cidofovir Approved Phase 4,Phase 2,Phase 1 113852-37-2 60613
2
Polihexanide Approved, Investigational Phase 4 28757-47-3
3
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
4
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
5
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Disinfectants Phase 4
15 Anti-Infective Agents, Local Phase 4
16 Biguanides Phase 4
17 Hypoglycemic Agents Phase 4
18 Chlorhexidine gluconate Phase 4
19 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
21 MF59 oil emulsion Phase 4
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 interferons Phase 4,Phase 2,Phase 3,Phase 1
25 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
26 insulin Phase 4,Phase 3
27 Insulin, Globin Zinc Phase 4,Phase 3
28
Azithromycin Approved Phase 3,Not Applicable 83905-01-5 447043 55185
29
Cetuximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 205923-56-4 56842117 2333
30
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
31
tannic acid Approved Phase 3 1401-55-4
32
Penicillin G Approved, Vet_approved Phase 3 61-33-6 5904
33
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
34
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
35
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
36
Cevimeline Approved Phase 3 107233-08-9 25137844 83898
37
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
38
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6 774
39
Doxepin Approved, Investigational Phase 3 1668-19-5 667468 667477
40
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
41
Promethazine Approved, Investigational Phase 3 60-87-7 4927
42
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
43
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
44
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
45
Zinc sulfate Approved, Investigational Phase 3,Not Applicable 7733-02-0
46
Zinc Approved, Investigational Phase 3,Not Applicable 7440-66-6 32051
47 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
48
Lapatinib Approved March 2007, Investigational Phase 3,Phase 2 231277-92-2, 388082-78-8 208908 9941095
49 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 438)
# Name Status NCT ID Phase Drugs
1 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 Use of Cidofovir for Recurrent Respiratory Papillomatosis Completed NCT00205374 Phase 4 Cidofovir;Placebo
4 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Completed NCT02087384 Phase 4 Placebo
5 A Health Belief Model Based Intervention to Increase Human Papilloma Virus (HPV) Vaccination Among College Men Completed NCT01431079 Phase 4
6 Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine Completed NCT01740245 Phase 4
7 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
8 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
9 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
10 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
11 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
12 Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study) Recruiting NCT03391921 Phase 4
13 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
14 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
15 GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose Not yet recruiting NCT03943875 Phase 4
16 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Not yet recruiting NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
17 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
18 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
19 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
20 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Unknown status NCT01995721 Phase 3
21 Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients Unknown status NCT03153566 Phase 3
22 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
23 Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine Completed NCT00316706 Phase 3
24 Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18. Completed NCT00196924 Phase 3
25 Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Completed NCT00169494 Phase 3
26 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) Completed NCT00380367 Phase 3
27 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18 Completed NCT00122681 Phase 3
28 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Completed NCT00196937 Phase 3
29 Efficacy and Tolerability Study of V501 in Japanese Males (V501-122) Completed NCT01862874 Phase 3
30 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3
31 A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020) Completed NCT02114385 Phase 3
32 Effect of Vaccination in Patients With Recurrent Respiratory Papillomatosis Completed NCT01375868 Phase 3
33 Safety and Tolerability Study of V501 in Japanese Boys (V501-200) Completed NCT02576054 Phase 3
34 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
35 Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Completed NCT00345878 Phase 3
36 Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women Completed NCT00344032 Phase 3
37 Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age Completed NCT00423046 Phase 3
38 Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) Completed NCT00157950 Phase 3
39 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects Completed NCT00578227 Phase 3
40 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years Completed NCT00485732 Phase 3
41 A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018) Completed NCT00092547 Phase 3
42 Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls Completed NCT01381575 Phase 3
43 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age Completed NCT00552279 Phase 3
44 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3 Topical imiquimod therapy
45 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
46 A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008). Completed NCT01254643 Phase 3
47 Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea Completed NCT01955252 Phase 3 Azithromycin
48 Glizigen-Viudid-External Anogenital Warts in Children and Adolescents Completed NCT01111344 Phase 3
49 Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age Completed NCT00492544 Phase 3
50 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years Completed NCT00456807 Phase 3

Search NIH Clinical Center for Papilloma

Inferred drug relations via UMLS 74 / NDF-RT 52 :
Sources

Genetic Tests for Papilloma

About this section
Sources

Anatomical Context for Papilloma

About this section

MalaCards organs/tissues related to Papilloma:

42
Testes, Skin, Cervix, T Cells, Prostate, Kidney, Bone
Sources

Publications for Papilloma

About this section

Articles related to Papilloma:

(show top 50) (show all 4875)
# Title Authors Year
1
Association of Bacterial Vaginosis and Human Papilloma Virus Infection With Cervical Squamous Intraepithelial Lesions. ( 31065675 )
2019
2
Electrocoagulation of biliary papillomatosis during choledochoscopy. ( 30658359 )
2019
3
Surgical treatment of malignant biliary papillomatosis invading adjacent organs: A case report. ( 30705903 )
2019
4
Is human papillomavirus associated with breast cancer or papilloma presenting with pathologic nipple discharge? ( 30785026 )
2019
5
Hemoptysis and Bronchiolitis Obliterans in Children with Recurrent Respiratory Papillomatosis: Adverse Reactions to Nebulized Cidofovir. ( 30611599 )
2019
6
Human papilloma virus DNA-biomarker analysis for cervical cancer: Signal enhancement by gold nanoparticle-coupled tetravalent streptavidin-biotin strategy. ( 31078598 )
2019
7
ТР53 Codon 72 Polymorphism and Human Papilloma Virus-Associated Cervical Cancer in Kyrgyz Women ( 31030474 )
2019
8
Prospective cohort study examining cervical cancer screening methods in HIV-positive and HIV-negative Cambodian Women: a comparison of human papilloma virus testing, visualization with acetic acid and digital colposcopy. ( 30804036 )
2019
9
Health professionals' willingness to pay and associated factors for human papilloma virus vaccination to prevent cervical cancer at College of Medicine and Health Sciences University of Gondar, Northwest Ethiopia. ( 30678735 )
2019
10
Awareness and Knowledge of Human Papilloma Virus and Cervical Cancer in Women with High Pap Uptake. ( 30415376 )
2019
11
New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. ( 30370796 )
2019
12
Facilitators and Barriers of Cervical Cancer Screening and Human Papilloma Virus Vaccination Among Somali Refugee Women in the United States: A Qualitative Analysis. ( 30170512 )
2019
13
Association of Base Excision Repair Gene hOGG1 Ser326Cys Polymorphism with Susceptibility to Cervical Squamous Cell Carcinoma and High-Risk Human Papilloma Virus Infection in a Chinese Population. ( 30648893 )
2019
14
Apparent diffusion coefficients are closely related with high-risk human papilloma virus infection in cervical squamous cell carcinoma patients. ( 30722670 )
2019
15
The management of numerous carcinomatous sequelae of human papilloma virus in an allogeneic stem cell transplant patient with chronic graft versus host disease. ( 30733986 )
2019
16
Intraductal papilloma of the male breast: a case report and review of the literature. ( 30788101 )
2019
17
Intraductal papilloma of the breast - management. ( 30860277 )
2019
18
Comprehensive analysis of HPV infection, EGFR exon 20 mutations and LINE1 hypomethylation as risk factors for malignant transformation of sinonasal-inverted papilloma to squamous cell carcinoma. ( 30411788 )
2019
19
Imaging predictors for malignant transformation of inverted papilloma. ( 30515841 )
2019
20
Outcomes of sinonasal inverted papilloma resection by surgical approach: an updated systematic review and meta-analysis. ( 30748098 )
2019
21
Cervical nodal metastasis after malignant conversion of sinonasal inverted papilloma: Report of a rare case and literature review. ( 30846175 )
2019
22
Surgical outcomes of sinonasal inverted papilloma: a 17 year review. ( 30852156 )
2019
23
EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma. ( 30916792 )
2019
24
Surgical management of inverted papilloma involving the frontal sinus: a practical algorithm for treatment planning. ( 30936576 )
2019
25
Putative biomarkers of malignant transformation of sinonasal inverted papilloma into squamous cell carcinoma. ( 30991875 )
2019
26
Inverted papilloma of the conjunctiva. ( 30997398 )
2019
27
Comparative transcriptome analysis of sinonasal inverted papilloma and associated squamous cell carcinoma: Out-HOXing developmental genes. ( 31041828 )
2019
28
An Inverted Papilloma Arising From the Basal Lamella of the Middle Turbinate: An Endoscopic View. ( 31106584 )
2019
29
Morphologic, intraoperative, and histologic risk factors for sinonasal inverted papilloma recurrence. ( 31112326 )
2019
30
Histopathological features of juvenile-onset laryngeal papillomatosis related to severity. ( 30623508 )
2019
31
Management of laryngeal papillomatosis using coblation: another option of surgical intervention. ( 30798335 )
2019
32
Pathological mechanisms of laryngeal papillomatosis based on laryngeal epithelial characteristics. ( 30828624 )
2019
33
Implication of low risk human papillomaviruses, HPV6 and HPV11 in laryngeal papillomatosis in Burkina Faso. ( 30799210 )
2019
34
Gallbladder Papilloma in a Child Unmasking Metachromatic Leukodystrophy: A Case Report With Review of Literature. ( 30912695 )
2019
35
Safety concerns with human papilloma virus immunization in Japan: Analysis and evaluation of Nagoya City's surveillance data for adverse events. ( 30693675 )
2019
36
Expression of p16 and p27 protein in cervical exfoliated cells and its relationship with high risk human papilloma virus in cervical lesions. ( 30693740 )
2019
37
Prophylactic human papilloma virus vaccination in head and neck: indications and future perspectives. ( 30694913 )
2019
38
Excision recommended in high-risk patients: Revisiting the diagnosis of papilloma on core biopsy in the context of patient risk. ( 30697873 )
2019
39
Prevalence of high-risk human papilloma virus in women with high-grade squamous cell intraepithelial lesions in Botswana using Abbott RealTime HPV assay. ( 30699172 )
2019
40
Stereophotogrammetric three-dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus-induced skin lesions. ( 30720900 )
2019
41
Molecular Genetic Study to Detect Prevalence of High-risk Human Papilloma Virus Strains (type 16 and 18) in Cervical Lesions and Asymptomatic Healthy Subjects of Rural Central India. ( 30745737 )
2019
42
Molecular Diagnosis of Human Papilloma Virus by PCR. ( 30755567 )
2019
43
High-risk human papilloma virus testing improves diagnostic performance to predict moderate-to-high grade anal intraepithelial neoplasia in HIV-infected men who have sex with men in low-to-absent cytological abnormalities. ( 30770528 )
2019
44
Impact of human papilloma virus in patients with oral and oropharyngeal squamous cell carcinomas. ( 30777194 )
2019
45
Two-Year Results of Community-Based Screening Program for Human Papilloma Virus DNA in Çorum Province. ( 30793760 )
2019
46
Prevalence of epithelial abnormalities and high-risk human papilloma virus in cervicovaginal Pap smears of population subgroups as a guide toward evidence-based best practice. ( 30801970 )
2019
47
Human Papilloma Virus Infection. ( 30817264 )
2019
48
Knowledge, Attitudes and Practices Regarding Human Papilloma Virus Communication and Vaccine Advocacy Among Minnesota Dentists and Dental Hygienists. ( 30819844 )
2019
49
Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. ( 30838648 )
2019
50
Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis. ( 30842242 )
2019
Sources

Variations for Papilloma

About this section
Sources

Expression for Papilloma

About this section
Search GEO for disease gene expression data for Papilloma.
Sources

Pathways for Papilloma

About this section

Pathways related to Papilloma according to GeneCards Suite gene sharing:

(show all 40)
# Super pathways Score Top Affiliating Genes
1
Developmental Biology 67
Show member pathways
 13.47 FLG IVL KRT10 KRT13 KRT14 KRT20
2
PI3K-Akt signaling pathway 38
Show member pathways
 12.95 CDKN1A IL4 PTEN RB1 TGFA TP53
3
Endometrial cancer 38
Show member pathways
 12.86 CDKN1A CDKN2A PTEN RB1 TGFA TP53
4
Gastric cancer 38
Show member pathways
 12.69 CDKN1A CDKN2A CDKN2B PTEN RB1 TGFA
5
Glioma 38
Show member pathways
 12.63 CDKN1A CDKN2A CDKN2B PTEN RB1 TGFA
6
Pathways in cancer 38
12.58 CDKN1A CDKN2A CDKN2B IL4 PTEN RB1
7
Mitotic G1-G1/S phases 67
Show member pathways
 12.56 CDKN1A CDKN2A CDKN2B RB1 TP53
8
Cytoskeletal Signaling 4
12.5 AMOT KRT10 KRT13 KRT20 KRT5 KRT8
9
DNA Damage 4
12.45 CDKN1A CDKN2A RB1 TP53
10
DNA Damage Response 1
Show member pathways
 12.38 CDKN1A CDKN2A PTEN RB1 TP53
11
Cell cycle 38 1
12.37 CDKN1A CDKN2A CDKN2B RB1 TP53
12
Human T-cell leukemia virus 1 infection 38
12.36 CDKN1A CDKN2A CDKN2B RB1 TP53
13
Development IGF-1 receptor signaling 23
Show member pathways
 12.35 CDKN1A IL4 PTEN TP53
14
Cyclins and Cell Cycle Regulation 65
Show member pathways
 12.33 CDKN1A CDKN2A CDKN2B RB1 TP53
15
p53 Signaling 65
Show member pathways
 12.23 CDKN1A PTEN RB1 TP53
16
Cell cycle Role of SCF complex in cell cycle regulation 23
Show member pathways
 12.2 CDKN1A CDKN2A CDKN2B RB1
17
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.16 CDKN1A PTEN RB1 TP53
18
Viral carcinogenesis 38
12.15 CDKN1A CDKN2A CDKN2B RB1 TP53 UBE3A
19
SMAD Signaling Network 65
12.04 CDKN1A CDKN2A RB1 TP53 UBE3A
20
Direct p53 effectors 1
12.03 CDKN1A PTEN RB1 TGFA TP53
21
DNA Damage Response (only ATM dependent) 1
11.99 CDKN1A CDKN2A PTEN TP53
22
Cytoskeleton remodeling Neurofilaments 23
Show member pathways
 11.96 KRT13 KRT14 KRT5 KRT8
23
Glioblastoma Multiforme 65
11.9 CDKN1A CDKN2A PTEN RB1 TP53
24
Androgen receptor signaling pathway 1
11.87 CDKN1A PTEN RB1 UBE3A
25
Senescence and Autophagy in Cancer 1
11.86 CDKN1A CDKN2A PTEN RB1 TP53
26
Cellular senescence (KEGG) 38
11.84 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
27
Retinoblastoma (RB) in Cancer 1
11.8 CDKN1A RB1 TP53
28
Small cell lung cancer 38
11.77 CDKN1A CDKN2B PTEN RB1 TP53
29
Bladder cancer 1 38
11.73 CDKN1A CDKN2A RB1 TP53
30
Platinum drug resistance 38
11.71 CDKN1A CDKN2A TP53
31
Transcription_P53 signaling pathway 23
11.68 CDKN1A CDKN2A RB1 TP53 UBE3A
32
Keratinization 67
Show member pathways
 11.68 FLG IVL KRT10 KRT13 KRT14 KRT20
33
Glucocorticoid receptor regulatory network 1
11.63 CDKN1A IL4 KRT14 KRT5 TP53
34
Photodynamic therapy-induced AP-1 survival signaling. 1
11.53 CDKN1A CDKN2A RB1 TP53
35
Oncogene Induced Senescence 67
11.32 CDKN2A CDKN2B TP53
36
Inhibition of Ribosome Biogenesis by p14(ARF) 65
11.12 CDKN2A RB1 TP53
37
TP53 Network 1
Show member pathways
 11.11 CDKN1A CDKN2A TP53
38
Integrated Cancer Pathway 1
11.02 CDKN1A CDKN2B PTEN RB1 TP53
39
LncRNA-mediated mechanisms of therapeutic resistance 1
10.75 CDKN1A TP53
40
Transcriptional activation of p53 responsive genes 67
Show member pathways
 10.57 CDKN1A TP53
Sources

GO Terms for Papilloma

About this section

Cellular components related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.86 AMOT CDKN1A CDKN2A CDKN2B FLG IVL
2 keratin filament GO:0045095 9.56 KRT13 KRT14 KRT5 KRT8
3 PML body GO:0016605 9.54 PTEN RB1 TP53
4 cornified envelope GO:0001533 9.5 FLG IVL KRT10
5 intermediate filament GO:0005882 9.17 FLG KRT10 KRT13 KRT14 KRT20 KRT5
6 nucleus GO:0005634 10.06 AMOT CDKN1A CDKN2A CDKN2B FLG KRT10

Biological processes related to Papilloma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 CDKN1A IL4 PTEN TGFA TP53
2 negative regulation of cell proliferation GO:0008285 9.91 CDKN1A CDKN2A CDKN2B PTEN RB1 TP53
3 G1/S transition of mitotic cell cycle GO:0000082 9.75 CDKN1A CDKN2A RB1
4 keratinocyte differentiation GO:0030216 9.71 FLG IVL KRT10
5 negative regulation of epithelial cell proliferation GO:0050680 9.7 CDKN2B PTEN RB1
6 peptide cross-linking GO:0018149 9.67 FLG IVL KRT10
7 Ras protein signal transduction GO:0007265 9.67 CDKN1A CDKN2A RB1 TP53
8 regulation of cyclin-dependent protein serine/threonine kinase activity GO:0000079 9.65 CDKN1A CDKN2B PTEN
9 negative regulation of phosphorylation GO:0042326 9.58 CDKN1A CDKN2A CDKN2B
10 hemidesmosome assembly GO:0031581 9.57 KRT14 KRT5
11 response to arsenic-containing substance GO:0046685 9.56 CDKN1A PTEN
12 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.56 CDKN1A CDKN2B PTEN RB1
13 hepatocyte apoptotic process GO:0097284 9.55 KRT8 RB1
14 cell cycle arrest GO:0007050 9.55 CDKN1A CDKN2A CDKN2B RB1 TP53
15 prostate gland growth GO:0060736 9.51 PTEN UBE3A
16 replicative senescence GO:0090399 9.5 CDKN1A CDKN2A TP53
17 keratinization GO:0031424 9.5 IVL KRT10 KRT13 KRT14 KRT20 KRT5
18 signal transduction by p53 class mediator GO:0072331 9.46 CDKN1A TP53
19 cornification GO:0070268 9.23 FLG IVL KRT10 KRT13 KRT14 KRT20

Molecular functions related to Papilloma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 CDKN1A CDKN2A CDKN2B PTEN TP53
2 ubiquitin protein ligase binding GO:0031625 9.67 CDKN1A RB1 TP53 UBE2L3
3 disordered domain specific binding GO:0097718 9.43 CDKN2A RB1 TP53
4 structural constituent of epidermis GO:0030280 9.4 FLG KRT10
5 structural molecule activity GO:0005198 9.26 FLG IVL KRT10 KRT13
6 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.8 CDKN1A CDKN2A CDKN2B
7 protein binding GO:0005515 10.11 AMOT CDKN1A CDKN2A CDKN2B FLG IL4
Sources

Sources for Papilloma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....